文献速递胸部肿瘤

奥希替尼联合吉非替尼治疗C797S和T790M突变的EGFR突变非小细胞肺癌

Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-08-24

本文报告首例已知的T790M与C797S反式构型的EGFR突变非小细胞肺癌患者,接受吉非替尼联合奥希替尼治疗。联合治疗2周内出现快速临床改善,血浆C797S亚克隆快速下降,但EGFR外显子19缺失驱动突变和T790M耐药突变水平持续上升,患者于联合治疗开始后6周死于疾病进展,联合治疗未观察到不良事件。

要点

  • 首例已知T790M与C797S反式构型患者接受吉非替尼联合奥希替尼治疗。
  • 联合治疗2周内快速临床改善,血浆C797S亚克隆快速下降。
  • 驱动突变和外显子19缺失及T790M水平持续上升,6周后死于疾病进展,无不良事件。

核心结论

  • 据作者所知,这是首例根据T790M和C797S突变等位基因构型定制的EGFR酪氨酸激酶抑制剂联合治疗,导致短暂的临床改善且无毒性。

研究设计与样本

  • 本研究报告一例携带T790M和C797S反式突变的患者,在多次治疗后出现疾病进展,使用Oncomine Lung cfDNA Assay(Thermo Fisher Scientific, Waltham, MA)对血浆进行测序,并通过微滴数字聚合酶链反应监测血浆循环肿瘤DNA。

主要发现

  • 测序显示T790M和C797S突变呈反式。
  • 联合治疗开始2周内出现快速临床改善,同时检测到血浆C797S突变亚克隆快速下降。
  • 然而,循环肿瘤DNA中EGFR外显子19缺失驱动突变和T790M耐药突变水平持续上升,患者于联合治疗开始后6周死于疾病进展。
  • 联合治疗未观察到不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor has demonstrated efficacy in tumors harboring the EGFR T790M resistance mutation. Inevitably, resistance to third-generation inhibitors results in disease progression, with the EGFR C797S mutation being one of several resistance pathways identified to date. On the basis of preclinical data, we report what is the first known case of a patient harboring the T790M and C797S mutations in trans treated with combination gefitinib and osimertinib. METHODS: On development of progressive disease after multiple therapies, the patient's plasma was sequenced using the Oncomine Lung cfDNA Assay (Thermo Fisher Scientific, Waltham, MA). Subsequent monitoring of circulating tumor DNA in plasma was performed by droplet digital polymerase chain reaction. RESULTS: Sequencing showed that the T790M and C797S mutations were in trans. Within 2 weeks of commencement of combination therapy, rapid clinical improvement occurred. Accompanying this, a rapid decline in the C797S mutation subclone in plasma was detected. However, the levels of the EGFR exon 19 deletion driver mutation and the T790M resistance mutation in the circulating tumor DNA continued to rise and the patient died from progressive disease 6 weeks after commencement of combination therapy. There were no adverse events seen with the combination therapy. CONCLUSION: This is, to the best of our knowledge, the first reported case of combination EGFR tyrosine kinase inhibitor therapy tailored to the allelic conformation of T790M and C797S mutation that resulted in brief clinical improvement without toxicity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Arulananda S, Do H, Musafer A, et al. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28843359. doi:10.1016/j.jtho.2017.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。